

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

HOUGHTON ET AL.

APPLICATION NO: 10/530,618

FILED: FEBRUARY 23, 2006

FOR: USE OF IMATINIB (GLIVEC, STI-571) TO INHIBIT BREAST
CANCER RESISTANCE PROTEIN (BCRP)-MEDIATED
RESISTANCE TO THERAPEUTIC AGENTS

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

PETITION FOR EXTENSION OF TIME

Sir:

The Office Action of September 14, 2007 has a shortened statutory time set to expire on October 14, 2007. A three-month extension is hereby requested pursuant to 37 CFR §1.136(a).

Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$ 1050 for payment of the extension fee. An additional copy of this paper is here enclosed. The Commissioner is hereby authorized to charge any additional fees under 37 CFR §1.17 which may be required, or credit any overpayment, to Account No. 19-0134 in the name of Novartis.

Respectfully submitted,

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080

Date: 12/19/07



Oona A. Manzari
Attorney for Applicants
Reg. No. 48,152
Phone No. (862) 778-7852